A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation
Latest Information Update: 25 Jun 2025
At a glance
Most Recent Events
- 25 Apr 2025 Planned number of patients changed from 20000 to 20296.
- 25 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2024 Planned number of patients changed from 15500 to 20000.